BioXcel Therapeutics, Inc.
BTAI
$1.85
$0.169.47%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 71.03% | -80.62% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 71.03% | -80.62% | |||
| Cost of Revenue | -28.89% | 1,787.10% | |||
| Gross Profit | 51.26% | -191.75% | |||
| SG&A Expenses | -46.71% | -18.70% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -22.41% | -20.46% | |||
| Operating Income | 23.86% | 16.42% | |||
| Income Before Tax | 20.45% | -64.48% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 20.45% | -64.48% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 20.45% | -64.48% | |||
| EBIT | 23.86% | 16.42% | |||
| EBITDA | 24.00% | 16.50% | |||
| EPS Basic | 30.65% | -56.19% | |||
| Normalized Basic EPS | 21.97% | -54.33% | |||
| EPS Diluted | 30.65% | -56.19% | |||
| Normalized Diluted EPS | 21.97% | -54.33% | |||
| Average Basic Shares Outstanding | 14.71% | 5.31% | |||
| Average Diluted Shares Outstanding | 14.71% | 5.31% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||